olivLaw · US equity research
Kenvue Inc. KVUE
Perfumes, Cosmetics & Other Toilet Preparations · SIC 2844 · Vertical: Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844)
Kenvue Inc. (KVUE) is the world's largest pure-play consumer health company by revenue, with net sales of 15.1 billion USD in fiscal 2025. In the second quarter of 2026, net sales rose 3.0% and organic sales 1.6%. The company is in a pending merger with Kimberly-Clark, with closing expected in the fourth quarter of 2026.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 30 Oct 2026, Kenvue Inc. (KVUE) stock was 19.31 USD (−1.28% on the day), with market capitalisation 37.1 bn USD, P/E 21.9 on diluted EPS of 0.88 USD over the last 12 months, dividend yield 5.40%, beta 0.16, 52-week range 14.37–19.88 USD. Latest reported quarter (Q3 2026): revenue of 3.9 bn USD (+3.2% YoY), net income of 430.0 m USD (+8.0% YoY), diluted EPS 0.22 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 60.0
- strong (55–70)
- Bollinger (20, 2)
- 16.99 – 20.30
- in the upper half of the band · %B 0.70 · band width 17.7%
- SMA 50 / 200
- 18.41 / 18.19
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.40 / 0.31
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +9.3% | −1.1% | +10.4 pp | — |
| 3 months | +0.4% | −0.5% | +0.8 pp | — |
| 6 months | +10.8% | +4.4% | +6.4 pp | — |
| Year to date | +11.9% | +12.3% | −0.4 pp | — |
| 1 year | +35.6% | +13.5% | +22.1 pp | +4.5% |
| 3 years | +3.8% | +76.4% | −72.6 pp | −14.8% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 27 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.7 bn | 3.7 bn | 3.8 bn | 3.8 bn | 3.8 bn | 3.9 bn | 4.0 bn | 3.9 bn |
| Cost of revenue | 1.6 bn | 1.6 bn | 1.6 bn | 1.5 bn | 1.6 bn | 1.6 bn | 1.7 bn | 1.6 bn |
| Gross profit | 2.1 bn | 2.2 bn | 2.3 bn | 2.2 bn | 2.1 bn | 2.3 bn | 2.3 bn | 2.3 bn |
| Research & development | 106.0 m | 99.0 m | 91.0 m | 94.0 m | 98.0 m | 84.0 m | 94.0 m | 96.0 m |
| SG&A | 1.5 bn | 1.5 bn | 1.5 bn | 1.5 bn | 1.5 bn | 1.5 bn | 1.5 bn | 1.6 bn |
| Operating income | 483.0 m | 558.0 m | 692.0 m | 629.0 m | 535.0 m | 767.0 m | 699.0 m | 706.0 m |
| Depreciation & amortisation | 150.0 m | 136.0 m | 142.0 m | 141.0 m | 138.0 m | 143.0 m | 145.0 m ≈ | 143.0 m ≈ |
| Interest expense | 108.0 m | 107.0 m | 107.0 m | 107.0 m | 109.0 m | 106.0 m | 103.0 m | 104.0 m |
| Pre-tax income | 346.0 m | 458.0 m | 588.0 m | 526.0 m | 427.0 m | 672.0 m | 598.0 m | 609.0 m |
| Income tax | 53.0 m | 136.0 m | 168.0 m | 128.0 m | 97.0 m | 198.0 m | 142.0 m | 179.0 m |
| Net income | 293.0 m | 322.0 m | 420.0 m | 398.0 m | 330.0 m | 474.0 m | 456.0 m | 430.0 m |
| Diluted EPS | 0.15 ≈ | 0.17 | 0.22 | 0.21 | 0.17 ≈ | 0.25 | 0.24 | 0.22 |
| Operating cash flow | 793.0 m | 428.0 m | 621.0 m ≈ | 294.0 m ≈ | 854.0 m | 489.0 m | 688.0 m ≈ | 700.0 m ≈ |
| Capex | 132.0 m | 179.0 m | 88.0 m ≈ | 98.0 m ≈ | 110.0 m | 139.0 m | 64.0 m ≈ | 80.0 m ≈ |
| Dividends paid | 393.0 m | 392.0 m | 393.0 m ≈ | 398.0 m ≈ | 398.0 m | 398.0 m | 398.0 m ≈ | 403.0 m ≈ |
| Share repurchases | 121.0 m | 63.0 m | 64.0 m ≈ | 70.0 m ≈ | 0 | 0 | 0 ≈ | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 25 percentile of its own 12-quarter history (min 20.2, median 25.7, max 42.9; quarters with earnings only).
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 15.1 bn | 15.4 bn | 15.5 bn | 15.1 bn |
| Revenue YoY | unavailable | +2.6% | +0.1% | −2.1% |
| Net income | 2.1 bn | 1.7 bn | 1.0 bn | 1.5 bn |
| Net income YoY | unavailable | −19.9% | −38.1% | +42.7% |
| Diluted EPS | 1.21 | 0.90 | 0.54 | 0.76 |
| Diluted EPS YoY | unavailable | −25.6% | −40.0% | +40.7% |
| net % | 13.8% | 10.8% | 6.7% | 9.7% |
| Free cash flow | 39.0 m | 2.7 bn | 1.3 bn | 1.7 bn |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 28 Dec 2025
- Cash
- 1.1 bn USD
- Financial debt
- 1.5 bn USD
- Net debt
- 391.0 m USD
- Equity
- 10.8 bn USD
- Total assets
- 27.1 bn USD
- Debt / equity
- 0.13x
- Current ratio
- 0.96x
- ROE
- 14.4%
- ROA
- 5.6%
- FCF margin
- 11.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | 15.1 bn | 15.4 bn | 15.5 bn | 15.1 bn | SEC (XBRL)· 20 Feb 2026verified |
| Cost of revenue | 6.6 bn | 6.8 bn | 6.5 bn | 6.3 bn | SEC (XBRL)· 20 Feb 2026verified |
| Gross profit | 8.4 bn | 8.6 bn | 9.0 bn | 8.8 bn | SEC (XBRL)· 20 Feb 2026verified |
| Research & development | 355.0 m | 399.0 m | 408.0 m | 382.0 m | SEC (XBRL)· 20 Feb 2026verified |
| SG&A | 5.5 bn | 6.1 bn | 6.3 bn | 6.1 bn | SEC (XBRL)· 20 Feb 2026verified |
| Operating income | 2.9 bn | 2.5 bn | 1.8 bn | 2.4 bn | SEC (XBRL)· 20 Feb 2026verified |
| Depreciation & amortisation | 731.0 m | 627.0 m | 622.0 m | 557.0 m | SEC (XBRL)· 20 Feb 2026verified |
| EBITDA | 3.7 bn ≈ | 3.1 bn ≈ | 2.5 bn ≈ | 3.0 bn ≈ | SEC (XBRL)· 20 Feb 2026derived |
| Interest expense | 0 | 250.0 m | 431.0 m | 430.0 m | SEC (XBRL)· 20 Feb 2026verified |
| Pre-tax income | 2.9 bn | 2.2 bn | 1.4 bn | 2.0 bn | SEC (XBRL)· 20 Feb 2026verified |
| Income tax | 847.0 m | 526.0 m | 385.0 m | 529.0 m | SEC (XBRL)· 20 Feb 2026verified |
| Net income | 2.1 bn | 1.7 bn | 1.0 bn | 1.5 bn | SEC (XBRL)· 20 Feb 2026verified |
| Diluted EPS | 1.21 | 0.90 | 0.54 | 0.76 | SEC (XBRL)· 20 Feb 2026verified |
| Weighted average diluted shares | 1.7 bn | 1.9 bn | 1.9 bn | 1.9 bn | SEC (XBRL)· 20 Feb 2026verified |
| Dividend per share | — | 0.40 | 0.81 | 0.83 | SEC (XBRL)· 20 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 740.0 m | 1.4 bn | 1.1 bn | 1.1 bn | SEC (XBRL)· 20 Feb 2026verified |
| Receivables | — | 2.1 bn | 2.2 bn | 2.4 bn | SEC (XBRL)· 20 Feb 2026verified |
| Inventories | — | 1.9 bn | 1.6 bn | 1.7 bn | SEC (XBRL)· 20 Feb 2026verified |
| Current assets | — | 6.1 bn | 5.5 bn | 5.7 bn | SEC (XBRL)· 20 Feb 2026verified |
| Property, plant & equipment, net | — | 2.0 bn | 1.8 bn | 2.2 bn | SEC (XBRL)· 20 Feb 2026verified |
| Goodwill | 9.8 bn | 9.3 bn | 8.8 bn | 9.5 bn | SEC (XBRL)· 20 Feb 2026verified |
| Intangibles (excl. goodwill) | — | 9.6 bn | 8.5 bn | 8.7 bn | SEC (XBRL)· 20 Feb 2026verified |
| Total assets | — | 27.9 bn | 25.6 bn | 27.1 bn | SEC (XBRL)· 20 Feb 2026verified |
| Accounts payable | — | 2.5 bn | 2.3 bn | 2.5 bn | SEC (XBRL)· 20 Feb 2026verified |
| Short-term debt | — | 599.0 m | 1.6 bn | 1.5 bn | SEC (XBRL)· 20 Feb 2026verified |
| Long-term debt | — | 7.7 bn | — | — | SEC (XBRL)· 01 Mar 2024verified |
| Current liabilities | — | 5.5 bn | 5.7 bn | 5.9 bn | SEC (XBRL)· 20 Feb 2026verified |
| Total liabilities | — | 16.6 bn | 15.9 bn | 16.3 bn | SEC (XBRL)· 20 Feb 2026verified |
| Equity | 20.5 bn † | 11.2 bn † | 9.7 bn † | 10.8 bn † | SEC (XBRL)· 20 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | 334.0 m | 3.2 bn | 1.8 bn | 2.2 bn | SEC (XBRL)· 20 Feb 2026verified |
| Capex | 295.0 m | 469.0 m | 434.0 m | 475.0 m | SEC (XBRL)· 20 Feb 2026verified |
| Free cash flow | 39.0 m ≈ | 2.7 bn ≈ | 1.3 bn ≈ | 1.7 bn ≈ | SEC (XBRL)· 20 Feb 2026derived |
| Investing cash flow | -171.0 m | -488.0 m | -425.0 m | -436.0 m | SEC (XBRL)· 20 Feb 2026verified |
| Financing cash flow | 0 | -2.5 bn | -1.6 bn | -1.8 bn | SEC (XBRL)· 20 Feb 2026verified |
| Dividends paid | 0 | 766.0 m | 1.6 bn | 1.6 bn | SEC (XBRL)· 20 Feb 2026verified |
| Share repurchases | — | 7.0 m | 235.0 m | 197.0 m | SEC (XBRL)· 20 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 58 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
30 Oct 2026Source: olivLaw, closing series
Market cap: 37.1 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation55
- Returns66
- Quality84
- Balance sheet75
- Growth1
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 10.84 – 42.27 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)16.63 – 25.43 (Mid 20.05)WACC 9.2% · starting FCFF 2.6 bn USD · terminal value share of EV 73%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): -1.4%
- Peers: EV/EBITDA34.55 – 42.27 (Mid 37.68)4 companies used · median multiple 22.1x · quartiles 20.3x – 24.8xCL, COTY, ELF, EPC
- Peers: P/E11.27 – 20.54 (Mid 14.71)5 companies used · median multiple 16.7x · quartiles 12.8x – 23.3xAXIL, CL, IPAR, ODD, UG
- Dividend discount (DDM)10.84 – 14.58 (Mid 12.44)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 58/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 18.3% | 80 (vs peers) | 10% |
| Net margin · Quality | 10.9% | 73 (vs peers) | 6% |
| FCF conversion · Quality | 138.3% | 100 (on a fixed band) | 6% |
| Revenue CAGR 3Y · Growth | 0.2% | 1 (on a fixed band) | 8% |
| EPS CAGR 3Y · Growth | -14.4% | 0 (on a fixed band) | 8% |
| Net debt / EBITDA · Balance sheet | 0.0x | 100 (vs peers) | 10% |
| Interest coverage · Balance sheet | 6.4x | 76 (on a fixed band) | 6% |
| Current ratio · Balance sheet | 1.0x | 13 (on a fixed band) | 4% |
| P/E (TTM) · Valuation | 21.9x | 57 (vs peers) | 10% |
| EV/EBITDA · Valuation | 11.4x | 33 (on a fixed band) | 10% |
| FCF yield · Valuation | 6.3% | 79 (on a fixed band) | 8% |
| Shareholder yield (distributions) · Returns | 4.3% | 61 (on a fixed band) | 6% |
| Payout ratio (FCF) · Returns | 68.3% | 74 (on a fixed band) | 4% |
Score groups
- Balance sheet75/100 · 3/3 factors with a value
- Growth1/100 · 2/2 factors with a value
- Quality84/100 · 3/3 factors with a value
- Returns66/100 · 2/2 factors with a value
- Valuation55/100 · 3/3 factors with a value
Memo
Kenvue Inc. (KVUE). Latest full fiscal year: 2025; data up to 2026-09-27.
Figures computed from the financial statements: revenue 15.1 bn USD in 2025; YoY growth -2.1%; net margin 10.9%; ROE 16.3%; net debt/EBITDA 0.0x.
The estimated value range is 13.95–22.98 USD per share (median of 4 methods, agreement: medium); assumptions are illustrative. Against the central value of 17.38 USD, the price of 19.31 USD leaves a potential of -10.0% (value / price − 1) and a margin of safety of -11.1% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 58/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 18.3%
- Net margin: 10.9%
- FCF conversion: 138.3%
- Net debt / EBITDA: 0.0x
- Interest coverage: 6.4x
- FCF yield: 6.3%
- Payout ratio (FCF): 68.3%
What contradicts it
- Revenue CAGR 3Y: 0.2%
- EPS CAGR 3Y: -14.4%
- Current ratio: 1.0x
Versus the vertical median
Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844) · same industry (4-digit SIC) · compared with 15 companies
The size band was not applied: too few companies would have remained; the vertical includes much smaller or larger companies.
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| CLColgate-Palmolive Company | 78.5 bn | 38.7 | 358.9% | 9.6% | +1.4% | +23% / +25% |
| KVUEKenvue Inc. | 37.1 bn | 21.9 | 16.3% | 10.9% | −2.1% | +36% / +4% |
| ELFe.l.f. Beauty, Inc. | 6.7 bn | 113.6 | 6.0% | 3.4% | +24.6% | +49% / −4% |
| IPARInterparfums, Inc. | 4.0 bn | 23.3 | 19.5% | 11.3% | +2.5% | +52% / −1% |
| COTYCoty Inc. | 3.1 bn | — | -18.5% | -10.4% | −1.5% | +5% / −70% |
| EPCEdgewell Personal Care Company | 1.4 bn | — | -6.2% | -4.2% | −1.3% | +66% / −15% |
| SLSNSolesence, Inc. | 64.6 m | — | -15.1% | -3.8% | +18.6% | −60% / +22% |
| AXILAxil Brands, Inc. | 38.2 m | 16.7 | 23.3% | 9.3% | +17.5% | +10% / unavailable |
| UGUnited-Guardian, Inc. | 31.5 m | 12.8 | 21.4% | 22.0% | −13.4% | +18% / −16% |
| CABRCaring Brands, Inc. | 9.3 m | — | -3,889.1% | -183,298.7% | unavailable | −13% / unavailable |
| BNKKBonk, Inc. | 9.3 m | — | -332.4% | -2,330.4% | +201.6% | −82% / −99% |
| YCBDcbdMD, Inc. | 4.5 m | — | -40.3% | -13.8% | −1.5% | −34% / −93% |
| HLNHaleon plc | — | — | 10.2% | 15.1% | −1.8% | −6% / +8% |
| ODDOddity Tech Ltd | — | 12.0 | 32.6% | 13.7% | +25.2% | −50% / −37% |
| ELEstee Lauder Companies Inc | — | 111.7 | 9.3% | 2.4% | +5.0% | +19% / −12% |
| YSGYatsen Holding Limited | — | — | -2.7% | -1.9% | +32.2% | −67% / −49% |
1- and 3-year price returns: for KVUE from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 10.89 Total return -40% · Per year -40% | 19.29 Total return 4% · Per year 4% | 29.11 Total return 56% · Per year 56% |
| 3 years | 9.66 Total return -40% · Per year -16% | 19.35 Total return 14% · Per year 4% | 32.19 Total return 84% · Per year 23% |
| 5 years | 8.58 Total return -40% · Per year -10% | 19.41 Total return 23% · Per year 4% | 35.59 Total return 115% · Per year 17% |
- Exit P/E± 4.84
- Net margin± 3.39
- Annual revenue growth± 2.90
- Annual dilution± 0.28
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Aug 2026; since then the company filed 8-K (30 Oct 2026 · results), 10-Q (30 Oct 2026).
In brief
Kenvue Inc. (KVUE) is the world's largest pure-play consumer health company by revenue, with net sales of 15.1 billion USD in fiscal 2025 1. In the second quarter of 2026, net sales rose 3.0% and organic sales 1.6% 3. The company is in a pending merger with Kimberly-Clark, with closing expected in the fourth quarter of 2026 2.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Kimberly-Clark mergerhigh
Completion depends on foreign regulatory approvals and other conditions, and delay or failure could affect operations and the share price 12.
- Acetaminophen and litigationhigh
Regulatory developments and citizen petitions on acetaminophen could lead to lower sales and new lawsuits 1.
- Tariffs and costsmedium
Import tariffs and retaliatory trade measures could raise supply chain costs 1.
- Goodwill impairmentmedium
The interim review of Skin Health and Beauty showed a thin cushion over carrying value; further market deterioration could lead to an impairment 1.
- Raw material volatilitymedium
The Middle East conflict and other geopolitical events could create volatility in the cost and availability of inputs 2.
Investment thesis
What would need to be true (bull case)
- Organic growth for three consecutive quarters and results meeting or exceeding plans in the first half of 2026 could indicate renewed momentum 3.
- A portfolio of well-known brands and recent launches could support market share in several categories 3.
- If the Kimberly-Clark merger completes, the announced synergies could create value for shareholders 1.
What to watch
- Completion of the Kimberly-Clark merger and foreign regulatory approvalsQ4 2026
- Organic sales and margin trends in Skin Health and BeautyQ3 2026
- Impact of tariffs and raw material costs on marginsnext 10-Q
- Developments in acetaminophen litigation and regulation2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Aug 2026; since then the company filed 8-K (30 Oct 2026 · results), 10-Q (30 Oct 2026).
The business
Kenvue aims to realize the extraordinary power of everyday care through three reportable segments, Self Care, Skin Health and Beauty, and Essential Health, with products marketed in more than 165 countries 1. Its portfolio includes Tylenol®, Zyrtec®, Neutrogena®, Aveeno®, BAND-AID® Brand and Listerine® 1. The company relies on in-house manufacturing that delivered about 60% of sales volume in fiscal 2025, with the rest supplied by third parties 1.
Market context
Recent organic growth points to stable demand in the company's categories, though macroeconomic uncertainty and the Middle East conflict could affect raw material and logistics costs 2.
Trends
- Trade tariffsheadwind
Tariffs imposed by the US government and retaliation by other countries could raise supply chain costs and affect consumers, if exposure is not offset by internal measures 1.
- Digital and eCommercetailwind
Digital strategy and eCommerce supported growth in the second quarter of 2026 across several segments, which could continue if the trend holds 3.
- Inflation and conflictheadwind
Volatility in raw material, logistics and transport costs linked to the Middle East conflict could weigh on margins if these pressures persist 2.
- Operational efficiencymixed
Productivity savings and optimization of the global supply chain have partly offset margin pressure, and the 2026 restructuring aims to reduce complexity 3.
Competitive position
The company names Haleon, Procter & Gamble and Reckitt Benckiser in Self Care, Beiersdorf, Estée Lauder and L’Oréal in Skin Health and Beauty, and Church & Dwight, Colgate-Palmolive and Kimberly-Clark in Essential Health 1. Private-label brands add pressure across all segments 1.
Competition includes both established companies and emerging niche brands that distribute through online or direct-to-consumer channels 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report04 Nov 2026Item 3.03 · Financial statements and exhibits
- Current report02 Nov 2026Termination of a material agreement · Acquisition or disposition of assets · Delisting notice · Item 3.03 · Item 5.01 · Departure or appointment of officers · Amendments to articles or bylaws · Other events · Financial statements and exhibits
- Quarterly report30 Oct 2026
- Current report30 Oct 2026Results of operations · Financial statements and exhibits
- Current report13 Oct 2026Material agreement · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report22 May 2026Shareholder vote
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-28 · SEC / Kenvue Inc. · 20 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-28 · SEC / Kenvue Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Kenvue Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.